Companies:
49,943
Total Market Cap:
142463740055621.56
Global Rank
#16825
Country Rank
#458
Market Cap
351.13 M
Price
5.17
Change (%)
2.14%
Volume
129,353
STCube's latest marketcap:
351.13 M
As of 07/27/2025, STCube's market capitalization has reached $351.13 M. According to our data, STCube is the 16825th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 351.13 M |
| Revenue (ttm) | 7.59 M |
| Net Income (ttm) | -15,170,383.82 |
| Shares Out | 67.93 M |
| EPS (ttm) | -0.28 |
| Forward PE | 0.00 |
| Ex-Dividend Date | 12/27/2002 |
| Earnings Date | 08/13/2025 |
Market Cap Chart
Data Updated: 07/27/2025
STCube's yearly market capitalization.
STCube has seen its market value grow from ₩31.32 B to ₩485.72 B since 2014, representing a total increase of 1,451.02% and an annual compound growth rate (CAGR) of 29.60%.
| Date | Market Cap(₩) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/27/2025 | ₩485.72 B | $351.13 M | -18.05% | 16825 |
| 12/30/2024 | ₩580.25 B | $388.77 M | 4.95% | 14653 |
| 12/28/2023 | ₩552.9 B | $425.74 M | -13.69% | 14059 |
| 12/29/2022 | ₩640.57 B | $506.05 M | 141.43% | 12168 |
| 12/30/2021 | ₩265.32 B | $222.87 M | -14.25% | 18215 |
| 12/30/2020 | ₩309.42 B | $284.66 M | -0.29% | 14854 |
| 12/30/2019 | ₩310.3 B | $266.86 M | -49.4% | 13359 |
| 12/28/2018 | ₩613.19 B | $545.74 M | 300.16% | 8686 |
| 12/28/2017 | ₩153.24 B | $142.51 M | 19.57% | 16211 |
| 12/29/2016 | ₩128.16 B | $105.09 M | 24% | 15728 |
Company Profile
About STCube, Inc.
STCube, Inc. is a biopharmaceutical company based in Seoul, South Korea, specializing in the development of innovative medicines. Formerly known as Schem Co., Ltd., the company rebranded to STCube, Inc. in April 2008.
Core Focus Areas
- Anti-Cancer Immunotherapeutics: Developing treatments targeting various cancers.
- Anti-Viral Drugs: Researching therapies to combat viral infections.
Platform Technologies
- In vivo RNAi ICP Target Discovery: Identifies immune checkpoint (ICP) targets.
- Glycosylation-Specific Antibody Development: Creates antibodies to mask glycosylation sites.
- ICP Functional Assay Platform: Enables in vivo/in vitro analysis for drug development.
Product Pipeline
- Preclinical Stage: Anti PD-L1 Ab, Anti PD-1 Ab, and Anti STT-005 (solid tumor).
- Phase-1 Trial: Anti STT-003 Ab (lung, head, and neck cancer).
- Small Molecule Inhibitor: STT-011 (pancreatic cancer).
- Other Candidates: Anti STT-012 Ab (breast/prostate cancer), Anti STT-013 Ab (solid tumor).
Founded: 1989 | Headquarters: Seoul, South Korea
Frequently Asked Questions
-
What is STCube's (KOSDAQ-052020) current market cap?As of 07/27/2025, STCube (including the parent company, if applicable) has an estimated market capitalization of $351.13 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does STCube (KOSDAQ-052020) rank globally by market cap?STCube global market capitalization ranking is approximately 16825 as of 07/27/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.